Clinical Trial News and Research

RSS

Adynovate approved for patients with Hemophilia A

The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.

15 Nov 2015

Analyzing potential TB vaccine

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe's biggest public health threats.

13 Nov 2015

Drug combination produces long-term responses in patients with mantle cell lymphoma

New research from Moffitt Cancer Center and its collaborators find that the drug combination rituximab plus lenalidomide was effective and produced long-term responses in patients with mantle cell lymphoma.

13 Nov 2015

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma.

11 Nov 2015

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company’s lead investigational oral treatment for Alzheimer’s disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.

11 Nov 2015

Intensive management of high blood pressure reduces rates of cardiovascular disease, lowers risk of death

Jackson T. Wright Jr., MD, PhD, and researchers from University Hospitals Case Medical Center presented new results from the Systolic Blood Pressure Intervention Trial (SPRINT) showing that in patients at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg resulted in lower rates of fatal and non-fatal major events or death compared to targeting systolic blood pressure to the usually recommended target of less than 140 mm Hg.

10 Nov 2015

Study compares new cardiopulmonary resuscitation with standard CPR in cardiac arrest

Continuous chest compression, touted as the new way to perform cardiopulmonary resuscitation, was not an improvement over standard CPR, according to findings published in the New England Journal of Medicine today. The University of Alabama at Birmingham was one of eight United States and Canadian universities involved in the study, the largest such study of out-of-hospital cardiac arrest ever conducted.

10 Nov 2015

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA therapeutics for patients with cancer and rare diseases, today announced that the company has commenced enrollment in a Phase 2 clinical trial of IMO-8400, an investigational TLR 7, 8 and 9 antagonist, in patients with dermatomyositis. Dermatomyositis is a rare and debilitating inflammatory muscle and skin disease associated with significant morbidity, decreased quality of life and an increased risk of premature death.

10 Nov 2015

L-DOPA drug may delay or prevent age-related macular degeneration

A drug already used safely to treat Parkinson's disease, restless leg syndrome and other movement disorders also could delay or prevent the most common cause of blindness affecting more than 9 million older Americans - age-related macular degeneration (AMD).

10 Nov 2015

Disclosing genetic risk for CHD results in lower low-density lipoprotein cholesterol

A group of researchers led by Mayo Clinic has discovered that disclosing genetic risk for coronary heart disease (CHD) results in lower low-density lipoprotein cholesterol (LDL), also known as bad cholesterol. The findings of the Myocardial Infarction Genes (MI-GENES) Study were presented today at the annual American Heart Association Scientific Sessions 2015 as a late-breaking clinical trial.

10 Nov 2015

Public policy needed to reduce stem cell tourism, say experts

The continued marketing and use of experimental stem cell-based interventions inside and outside the United States is problematic and unsustainable, according to a new paper by science policy and bioethics experts at Rice University's Baker Institute for Public Policy and Wake Forest University.

10 Nov 2015

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

In a major scientific breakthrough, a drug used to treat Parkinson's and related diseases may be able to delay or prevent macular degeneration, the most common form of blindness among older Americans.

10 Nov 2015

Brief manualized treatment helps people with problematic caffeine use lower caffeine consumption

Engaging in brief, cognitive-behavioral therapy is an effective treatment for helping people with problematic caffeine use lower their caffeine consumption, according to a new study coauthored by Laura M. Juliano, Ph.D., a professor of psychology at American University.

10 Nov 2015

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

For the first time, research shows that a type 2 diabetes drug significantly reduces hospitalizations and death from heart failure.

10 Nov 2015

AACR rapid and dramatic responses in TRK fusion patients

Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

9 Nov 2015

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Armaron Bio, a Melbourne-based drug development company focused on heart failure and other diseases, is pleased to announce that it has begun its Phase II clinical trial for NP202, its novel lead candidate drug for heart failure.

9 Nov 2015

Nightstar announces $35 million Series B financing round

NightstaRx Ltd, a biopharmaceutical company specialising in developing gene therapies for inherited retinal dystrophies, announces a $35 million Series B financing round. The round was led by New Enterprise Associates, one of the world's leading venture capital firms.

9 Nov 2015

$Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented$

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Takeda Pharmaceutical Company Limited today announced that it will present Phase 3 data from the TOURMALINE-MM1 ixazomib clinical trial at the 57th American Society of Hematology (ASH) Annual Meeting to be held in Orlando, Florida from December 5 to 8, 2015.

6 Nov 2015

Viralytics enters into clinical trial collaboration agreement with MSD

Viralytics Limited announced today that it has entered into a clinical trial collaboration agreement through subsidiaries of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. (known as MSD outside the United States and Canada) to evaluate the combination of Viralytics' investigational cancer immunotherapy CAVATAK, with MSD's KEYTRUDA, an anti-PD-1 (programmed death receptor-1) therapy.

6 Nov 2015

Novel culturally-informed treatment benefits caregivers of people with schizophrenia

Schizophrenia is a chronic, severe and disabling psychiatric disorder that affects about one percent of the population in the United States. Approximately 60 percent of those suffering from this condition live with a relative. Despite the fact that that family interventions have shown to significantly improve outcomes for individuals with schizophrenia, only about seven percent of patients with this illness receive any family therapy.

6 Nov 2015

Clinical Trial News and Research

Adynovate approved for patients with Hemophilia A

Analyzing potential TB vaccine

Drug combination produces long-term responses in patients with mantle cell lymphoma

Phase I clinical trial shows investigational anticancer therapeutic is safe, tolerable in lymphoma patients

Anavex reports safety and efficacy data of ANAVEX 2-73 Phase 2a trial in Alzheimer’s patients

Intensive management of high blood pressure reduces rates of cardiovascular disease, lowers risk of death

Study compares new cardiopulmonary resuscitation with standard CPR in cardiac arrest

Idera begins enrollment in IMO-8400 Phase 2 clinical trial for treatment of dermatomyositis

L-DOPA drug may delay or prevent age-related macular degeneration

Disclosing genetic risk for CHD results in lower low-density lipoprotein cholesterol

Public policy needed to reduce stem cell tourism, say experts

Drug used to treat Parkinson's and related diseases may delay or prevent macular degeneration

Brief manualized treatment helps people with problematic caffeine use lower caffeine consumption

Type 2 diabetes drug significantly reduces hospitalizations, death from heart failure

AACR rapid and dramatic responses in TRK fusion patients

Armaron Bio starts Phase 2 trial for novel lead candidate drug for heart failure

Nightstar announces $35 million Series B financing round

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Viralytics enters into clinical trial collaboration agreement with MSD

Novel culturally-informed treatment benefits caregivers of people with schizophrenia

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer